Iterative Scopes, a 2017 spinout of MIT led by Jonathan Ng, announced today it closed a $30 million Series A financing led by new investors Obvious Ventures, with participation from Eli Lilly, Johnson & Johnson Innovation—JJDC Inc., venture capital firms Breyer Capital and Seae Ventures, and other leading healthcare investors. Proceeds from the investments will be used to continue developing the company’s AI-driven computational tools that help identify appropriate treatments and guide clinical trials for patients suffering from gastrointestinal diseases.
Search
Recent Posts
See AllBy: Harrison Weber With venture capital pouring record amounts of money into Los Angeles tech, small startups are seeing a boon. Seed deals hit new highs in the first half of this year, topping $330 m
Key takeaways • Real-world evidence (RWE) has the potential to be useful across the entire healthcare ecosystem, including for clinical trials, care provision, determining treatment outcomes, and post
Invitae (NYSE: NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Ciitizen, a patient-centric consumer health tech company. Backed by a16z